Low-Dose Mifepristone in Fibroid Management: A Single-Center Prospective Study in Goa, India

This study aims to evaluate the efficacy and safety of low-dose mifepristone in managing symptomatic uterine fibroids in women of reproductive age. Uterine fibroids, common benign tumors, can cause significant symptoms like heavy bleeding, pain, and reproductive issues, traditionally managed through surgery or pharmacological treatments. Mifepristone, a progesterone receptor modulator, has shown promise in reducing fibroid size and alleviating symptoms with fewer side effects than traditional treatments. The study, conducted at Healthway Hospitals in Goa, India, will focus on women aged 18–49 with fibroids sized between 3-8 cm, assessing changes in fibroid size, symptom relief, and adverse effects. Results from similar studies suggest mifepristone can significantly reduce fibroid size, improve hemoglobin levels, and relieve menstrual bleeding and pain with minimal side effects, offering a potential non-surgical treatment option for symptomatic fibroids. The study will employ a prospective, observational design over two years, with data analyzed for descriptive statistics.